A REVIEW OF ANALYTICAL METHODS FOR DETERMINATION OF TYPE- II ANTIDIABETIC DRUGS IN PHARMACEUTICALS AND BIOLOGICAL MATRICES by RAMAKRISHNA, BADIKELA & MONDAL, SUMANTA
Vol 14, Issue 1, 2021
Online - 2455-3891 
Print - 0974-2441
A REVIEW OF ANALYTICAL METHODS FOR DETERMINATION OF TYPE- II ANTIDIABETIC 
DRUGS IN PHARMACEUTICALS AND BIOLOGICAL MATRICES
BADIKELA RAMAKRISHNA1*, SUMANTA MONDAL2
1Department of Pharmaceutical Analysis and QA, Guru Nanak Institutions Technical Campus, School of Pharmacy, Ibrahimpatnam, Ranga 
Reddy, Telangana, India. 2Department of Pharmaceutical Chemistry, GITAM Institute of Pharmacy, GITAM Deemed to be University, Gandhi 
Nagar, Rushikonda, Visakhapatnam, Andhra Pradesh, India. Email: logonanalysis@gmail.com
Received: 19 October 2020, Revised and Accepted: 23 November 2020
ABSTRACT
Its a meglitinide analog is an oral symptom designed to common hour aldohexose excursions. Through not an antidiabetic, it acts in AN analogous 
manner by binding to antidiabetic receptor likewise on alternative one distinct receptor-» closure of adenosine triphosphate dependent K+ channel-» 
of depolarization-» internal secretion unharnesses. Repaglinide induces fast onset short-lasting internal secretion discharged. It is administered 
antero every main meal to stabilize postprandial hyperglycemia; the dose ought to be emitted if a food material is incomprehensible. Because of 
less permanent action, it perhaps had a lower risk of the seriousness of hypoglycemia. Repaglinide is indicated solely in type-II DM as another to 
sulfonylureas, or to supplement metformin/long internal secretion. It ought to be avoided in disease. This review delivers a detail description totally 
different of various analytical ways were printed for the estimation of repaglinide and its combination medicine in prescription drugs and biological 
matrices. This assessment encompasses different analytical ways such as chemical analysis ways, aggressive liquid activity (HPLC), superior thin-layer 
activity (HPTLC), liquid chromatography-mass spectroscopic analysis (LC-MS), and ultra-performance liquid activity (UPLC), GC-MS, [LC-ESI-MS-MS], 
capillary activity (CE), titrimetric and chemical science technique, and designation study for the estimation of repaglinide and together with a mixture.
Keywords: Biological matrices, Chromatography, Repaglinide, Analytical methods, Type-II diabetic drugs, ICH guidelines.
INTRODUCTION
Repaglinide is a new carboxymethyl benzoic acid derivative, also 
known as 2-ethoxy -4-[2-[[3-methyl-1-[2-(1-piperidinyl) phenyl] butyl] 
amino]-2-oxoethyl] (Fig. 1). It is a novel prandial glucose regulator 
for the treatment of type-II diabetes mellitus [1]. It reduces fasting 
glucose concentrations in patients with type-II diabetes mellitus. It 
helps to control the blood sugar levels by pancreas increases insulin 
levels. Repaglinide is an oral anti hyperglycemia agent used for the 
treatment of non-insulin-dependent diabetes mellitus (NIDDM). 
It belongs to the meglitinide is an anti-Diabetic type-II class drug 
with of short-acting insulin secretagogues, which act by binding to 
the β cells of the pancreas, and it stimulates and releases the insulin 
secretion levels [2]. Repaglinide incites an insulin response to early 
meals reducing the postprandial blood glucose levels. May be 1 month 
of a course is needed for a decrease in fasting blood glucose levels 
is seen. Meglitinides may have a common effect on slight growth in 
weight. The total average weight gain caused by meglitinides appears 
to be lower than that is caused by sulfonylureas. Due to their own 
mechanism of action, meglitinides it may because hypoglycemia [3]. 
The risk is thought to be lower than that of sulfonyl urea’s since their 
action is presence on glucose-dependent. In addition to reducing 
postprandial and fasting blood sugar, meglitinides are shown to 
decrease glycosylated hemoglobin (HbA1c) levels, which are reflective 
of the last 8–10 weeks of glucose control. Repaglinide is thoroughly 
metabolized in the liver and excreted in bile salts. Approximately 
90% of a single orally administered dose is eliminated in the face and 
8% in urine. The chemical formula of C27 H36N2 O4 and it is soluble in 
methanol and methylene chloride. But practically insoluble in water-
solubility of approximately 20 µg/ml [4]. This review explores the 
reported analytical method, so far in the literature for the estimations 
of repaglinide in bulk drug, pharmaceutical formulation, and biological 
matrix. Various analytical methods such as spectrometric, high-
pressure liquid chromatography (HPLC), high-performance thin-layer 
chromatography (HPTLC), liquid chromatography-mass spectrometry 
(LC-MS), and ultra-performance liquid chromatography (UPLC), 
capillary electrophoresis (CE), GC-MS, LC-ESI/MS, and diagnosis study 
has been used for analysis of Repaglinide [5].
SAMPLE PREPARATION
Solubility
According, to the Bio-pharmaceutical organization, the Repaglinide 
falls in BCS Class-II, which means high solubility and high perm 
ableness [6]. The pH scale of a saturated water resolution of repaglinide 
is bigger than seven the Pka is 4.1–5.7 and partition coefficient is 3.8. 
The solubility of the drug was tested in solvents ordinarily used for 
analytical methodology [7].
Sample preparation strategies
About 90% of the whole analysis of your time relies on sample 
resolution preparation during a most of the strategies. The standard 
of sample resolution preparation may be a key issue for the success 
of study. In most of the chemical analysis methodology is employed 
to distil water, and in generally fuel is employed an agent sample. 
The sample resolution preparation methodology for the summary 
extraction of repaglinide from biological matrices (plasma, serum 
and urine) embody super molecule precipitation with acetonitrile 
(ACN) and fuel, solid section extraction (SPE) mistreatment methanol-
phosphate buffer (PB), and methanol-water [8].
ANALYTICAL METHODS
Spectrometry
In literature regarding some ways area unit mentioned, for the 
determination of repaglinide victimization chemical analysis, of that 
ten ways area unit for the estimation of repaglinide alone, whereas 
different the opposite is for quantifying the repaglinide together with 
other medicine substance. The epitome of reported chemical analysis 
ways indicating the fundamental the fundamental (λmax) solvent and 
limit of detection (LOD) is shown in Table 1.
Review Article
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HPLC
Biological samples
Method development and valid of liquid natural process technique 
for concurrent estimation of repaglinide, metformin, pioglitazone, 
sitagliptin, glibenclamide, and gliclazide - Applications for Counterfeit 
Drug Analysis, the actual RP-HPLC technique was developed, and wide 
used oral antidiabetic area unit antidiabetic drug coordination compound 
(MTF), with few ordinarily prescribed by oral anti-diabetics, namely, and 
repaglinide (RPG), gliclazide (GLZ), pioglitazone coordination compound 
(PGZ), sitagliptin phosphate (SIT), and glibenclamide (GLB). The activity 
technique is separation carryout using gradient elution mode, and this 
method was valid in keeping with ICH Guidelines [19].
Separation and quantification of eight kind-II antidiabetic medicine 
on a high- performance liquid chromatography: Its applications 
to human plasma assay. Technique development and an analytical 
supported isocratic RP-HPLC action technique were developed and 
valid for the quantification and separation of eight kind-II antidiabetic 
drugs: Repaglinide, Nate glinide, rosiglitazone, pioglitazone, glipizide, 
gliclazide, glibenclamide, and glimepiride for his or her applications are 
utilized in human plasma assay technique. Antidiabetic is utilized as IS. 
The analysis was performed on onyx C18 column (100×4.6 mm. 5 µm) 
employing a mixture of components [20].
Pharmaceutical samples
Analytical methods for the determination of repaglinide in bulk drugs 
and pharmaceutical dosage forms using RP-HPLC are shown in Table 2.
STABILITY INDICATING METHOD
In the literature few stability indicating methods are reported. Table 3 
shows the summary of the methods.
LC-MS
Validation of high-performance liquid chromatography-tandem mass 
spectrographic analysis (LC-MS /MS) technique was developed for the 
determination of repaglinide in human plasma. The analytical internal 
standard of, diazepam, is measure extracted from the plasma (25 m/L) 
by liquid-liquid extraction with diethyl ether–dichloromethane 
(60:40, v/v). And separation on an XDB-C18 column, detection was 
administered into API 4000 mass spectroscopy with an ESI interface 
operative in numerous reactions watching mode [38].
Method for determination of LC-MS of anti-diabetic drug repaglinide 
in human plasma, the strategy was valid and developed over a linear 
range, and also the dried residue was reconstituted with 500 µL of 
mobile part, and it absolutely was a cinematographic separation was 
achieved on a C18 analytical column, the strategy of the mode using 
MRM transitions m/Z 453.3>162.2 and m/Z 389.0>201.1 for the 
drug, and IS, severally. This technique was with success applicable 
for additional authentic human plasma samples from bio-equivalence 
studies [39].
Determination of liquid chromatography-tandem spectroscopic analysis 
of repaglinide and antidiabetic in human plasma and its application to 
pharmaceutical bioequivalence study, and therefore the technique was 
valid and developed for the simultaneous estimation of repaglinide 
and antidiabetic in human plasma employing a D6- antidiabetic and 
D5-Repaglinide an internal standard. When protein precipitation using 
acetonitrile because the precipitation solvent, each analytes and ISS 
were separated on a Venusil ASB C18 [150 mm× 4.6 mm, 5 µm] through 
gradient elution using acetonitrile – 10 mmol L-1 ammonium ion 
acetate because the mobile phase. The strategy is linear complete the 
0.2–60.0ng/ml concentration range of repaglinide and over the 4–1000 
ng/ml range of antidiabetic. A cinematographic complete run time of 
7.5 min was achieved. The valid technique was fully applied to clinical 
information [40].
A bio-analytical methodology using 96-blade in thin-film 
microextraction (TFME) and LC-MS/MS methodology for estimation 
of Repaglinide (RPG) and a couple of its main metabolites’ strategies 
were valid and developed for used of an in vitro metabolism study. The 
target analyses are extracted from the human microsomal medium 
by a 96-blade-TFME system using the low-price image “SPME multi-
sampler” using C18 coating. Methodology development and validation 
showed by recoveries of around 90% for each analyzer’s and also the 
methodology was applied to an in vitro metabolism study of Repaglinide 
using human liver microsomes and established to be required for these 
functions [41].
Degradation product is below the high temperature/humidity, UV/
Visible lightweight, in varied pH and oxidization are varied conditions 
Table 1: Summary of a spectrometric method for the analysis of repaglinide either alone or in combination with other drugs such as 
gliclazide (GLZ) and metformin (MET)
Compounds Methods Solvent/procedure LOD (µg/ml) λ max (nm) Ref.
REPA, MET HCL Second order method derivative Methanol: heptane sulfonates 
sodium [70:30 v/v]
1.01, 0.32–0.39 234, 252 [9]
REPA Zero order derivative method-A, first order 
derivative method-B [absorbance maxima]
Methanol and water 0.00772, 
−0.00864
245 [10]
REPA Spectrophotometric method methanol 1.15 241 [11]
REPA Shim-pack method methanol 0.5–0.1 235 [12]
MET, REPA First-order derivative method [absorbance], 
second order derivative [Q- absorbance ratio]
alcohol 0.378, 0.686 240, 292 [13]







MET, REPA UV Spectroscopic method Methanol-water 0.3–0.13 210 [15]
REPA Assay of UV spectrophotometric method methanol 0.278 237 [16]
REPA Spectrofluorimetric method methanol 0.9986 379, 282 [17]
Empagliflozin, MET Spectrofluorimetric method methanol 0.20, 0.19 225, 237 [18]
REPA, MET HCL Second order derivative methanol 1.01, 0.32, 0.39 234, 252 [9]
Fig. 1: Chemical structure of repaglinide
71
Asian J Pharm Clin Res, Vol 14, Issue 1, 2021, 69-76
 Ramakrishna and Mondal
of repaglinide and metformin. And second, a primary valid technique 
was LC-UV is examined, whether or not it is valid and determined those 
drugs within the presence of their own pharmaceutical degradation 
product and whether or not it’s similar for estimating the degradation 
kinetic process [42].
HPTLC
Assay of antidiabetic medication in bulk and optimized methodology 
of nanoemulsion by stability-indicating valid methodology of high-
performance thin-layer chromatography techniques, a simple selective, 
Table 2: Report of RP-HPLC method for determination of repaglinide either single or in a combination with other drugs in 
pharmaceutical dosage forms








[4.5 mm×150 mm, 5 µm]
ACN:ammonium formate, 
[60:40, v/v]
UV 244 1 10 [21]
An optimization of MET 
separation condition of 
REPA
BDS, Hypersil C18 
[150 mm×4.6 mm, 5µm]
ACN: phosphate buffer 
[60:40 v/v] with 1% 
triethylamine.
UV 254 0.8 135.6-18.15 [22]











Methanol:buffer [40:60v/v] UV 242 1.0 0.5–2.0 [24]
Simultaneous REPA with 
MET HCl
C18 Methanol-0.2%: heptane 
sulfonates sodium 
[70:30v/v]




Determinations of REPA 
in the tablet dosage form
Agilent TC-C18 and 
C21[250×4.6 mm, 5 µm]
Methanol:water [80:20v/v] UV 241 1.0 0.73 [11]
Determination of REPA RP-C18 Methanol:triethylamine 
with orthophosphoric acid 
[50:50v/v]
UV 235 1 0.5-0.1 [12]
Simultaneous with MET, 
REPA
YMC PACK AM ODS 




PDA 210 1 0.3, 0.13 [15]




Methanol: Phosphate buffer 
[70:30%v/v]
UV 230 1.0 - [25]
Assay method (PK, PD), 
studies





UV 245 1.5 1 [26]
Simultaneous with MET 
& REPA
Hypersil ODS C18 
[250 mm×4.6 mm, 5 µm]
ACN:ammonium 
acetate buffer [0.05M] 
[60:40%v/v]
PDA 271 3.13, 10.01 0.5-3.0 [27]
Estimation of REPA drugs Analytical 
C18[250mm×4.6mm, 
5µm
ACN:trifluoro acetic acid in 
a water [55:45%v/v]
UV 285 1 1.73 [28]
In vitro permeation 
analysis studies of REPA
RP C18 
[250 mm×4.6 mm, 5 µm]
ACN:ammonium acetate 
[70:30%v/v]
UV 240 1 0.1–1.2 [17]
Table 3: The summary of stability indicating HPLC methods for determination of repaglinide either alone or in combination with other drugs
Study aim Stress condition Detection Types of study Ref. 
REPA simultaneous with MET 
HCL in bulk drugs
Acid, alkali, oxidation, dry heat 
degradation
UV-230 Separation in presence of [dry heat] degradation 
product
[29]
REPA estimation with MET 
HCL in tablet dosage form
Acid, alkali, oxidation. UV-232 Separation in presence of degradation product [30]
MET simultaneous with REPA Thermal, photolytic, hydrolytic, 
and oxidative.
UV-PDA-210 Separation of MET and REPA force degradation 
product.
[31]
REPA in bulk drug dosage Acidic, alkaline, hydrolytic, and 
photolytic oxidation.
UV-237 Assay method of degradation absorbance [16]
REPA in tablets Oxidation UV-243 Degradation pathway [32]
REPA in pharmaceutical 
dosage
Stable to neutral and photolytic UV-278 Separation in presence of REPA in force 
degradation
[33]
Determination of REPA Acids, alkali, hydrolysis, oxidation UV-240 Separation in presence of REPA in degradation 
product
[34]
REPA in bulk and dosage 
forms
Hydrolysis, oxidation, photolysis, 
and thermal 
UV-216, 243 Separation in presence of REPA in degradation 
product
[35]
REPA in bulk drugs Photolytic degradation UV-237 Separation in presence of REPA degradation 
product
[36]
Determination of REPA, PGL, 
and RGL.
Acids, alkaline, oxidative UV-225, 220, 240 Separation in presence of degradations and their 
preparation with good extraction recoveries
[37]
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accurate, precise, and stability-indicating methodology of HPTLC, is 
analyzed by a repaglinide and each as pharmaceutical bulk product 
and in nanoemulsion pharmaceutical formulation methodology was 
valid. The technique was used in TLC metallic element pre-coated 
plates with colloid powder [G-60] F-254, as a stationary phase. The 
sample solvent system consists of chloroform/methanol/ammonia/
glacial ethanoic acid (7.5:1.5:0.9:0.1, v/v). Furthermore, the degraded 
product is nicely separated from the pure drug. Densitometric analysis 
of repaglinide ultraviolet illumination absorbance mode at 240 nm was 
distributed, the regression knowledge for the activity plots are going to 
be excellently showed [43].
An isocratic technique is precise, and rapid, selective, and economically, 
and reverse-phase HPTLC technique was established for the 
simultaneous estimation of product of metformin hydrochloride and 
repaglinide. HPTLC technique was developed and valid by employing 
a pre-coated silica gel G-60 F254 plates as stationary phase, using a 
methanol: ammonia sulfate (0.25%) (pH-5.7) (2.5:7.5, v/v) as mobile 
phase. The SP plates were scanned at roughly 243–236 nm for HP-LC 
and HP-TLC both are respectively [44].
The determination of HPTLC technique was developed by a quantitative 
estimation of repaglinide during a single pharmaceutical formulation 
(2 mg). The action technique of repaglinide on silica Gel-60 powder 
F-254 TLC plate is SP and employing a chloroform:methanol:ammonia 
(4.5:0.8:0.05 v/v) as a mobile phase. Repaglinide showed a Rf worth 
0.55±0.03 and scanned UV at 288 nm using Camag TLC Scanner three. 
The method development was to be success, used for determining the 
assay of repaglinide tablet formulations [45].
Repaglinide is a widely used meglitinide class drug to treat diabetes 
mellitus. The degradation product as per ICH guidelines (hydrolysis, 
photolysis, dry heat, and oxidation) and a sensitive optimized assayed, 
stability-indicating method as developed for repaglinide in bulk and 
pharmaceutical dosage forms. The peak purity and quality of the drug 
were observed. Using HPTLC method, aluminum plates precoated with 
Silica Gel 60 F254 is a stationary phase and mobile phase solution used 
to consisted of methanol:toluene (2:8) and quantitation was done at the 
wavelength found to be at 242 nm. The method was developed to be 
simple, specific, precise, and stability-indicating study [46].
High-performance thin-layer chromatography method has been A 
simple, accurate, precise, and rapid development and validated for 
the estimation of repaglinide in tablet dosage forms. The method 
development in TLC aluminum plates precoated with silica gel-G60-F 
254 as a stationary phase. The mobile phase is used as a mixture of 
chloroform:methanol (9:1) v/v. The detection of the spot was carried 
out UV at 254 nm. The analytical calibration curves were found to 
be linear between 300 and 3000 ng mL-1 Rf value is 0.41±0.018 
with a regression coefficient of 0.9991. The proposed methods can 
be successfully used to determine the drug content of marketed 
pharmaceutical product formulation. The determined by recovery 
studies was founds to be 97.98–98.89%. The proposed method was 
validated according to various ICH guidelines [47].
UPLC
Method development and validation of simple stability indicating by UPLC 
method for the determination of repaglinide in pharmaceuticals dosages, 
A simple, precise, and accurate stability-indicating isocratic reverse-phase 
ultra-performance liquid chromatography method are determined. The 
method was developed using Water Equity BEH C18 (100 Ó 2.1) mm, 
1.7 µm column with a mobile phase consisting of a mixture of potassium 
dihydrogen phosphate buffer of pH 3.2 and acetonitrile (40:60 v/v). The 
total run time for the assay was only 4 min. The elution compound was 
detected at 245 nm with a UV detector. The standardization curve of mean 
peak area versus concentration showed an excellent [48].
The detailed electrochemical method was study and novel voltmeter, 
and LC methods are presented for the determination of repaglinide 
(RPG) in pharmaceuticals. The HP-LC and UPLC methods are developed 
using core-shell columns with mobile phase solution consisting of 
50:50; ACN:water 0.05 % TFA; at PH: 3.0 (v/v) with UV detection at 
215 nm. Finally, the proposed development method was successfully 
applied for the determination of repaglinide in pharmaceutical dosage 
forms [49].
A Novel method for liquid chromatography method was developed 
for the simultaneous determination of the widely used oral 
antidiabetic, metformin hydrochloride with anti-diabetics comprising 
the meglitinides class in bulk, laboratory-prepared mixtures, and 
pharmaceutical products. It was applied in the presence of metformin-
reported by impurity (1-cyanoguanidine). Chromatography separation 
was achieved with isocratic elution mode using a mobile phase 
solution of acetonitrile: 0.01 M sodium dihydrogen phosphate (pH: 2.8) 
(67:33; v/v) flowing through a LiChrospher NH2 (amino) Agilent 
column (250 × 4.6 mm–5 µm) at a rate of 0.8 mL/min at ambient 
temperature in a run time of 4 min. The detections of UV were carried 
out at 220 nm. As per ICH guidelines, the present method was found 
to be rapid and simple, selective, economic, and needs for quality 
assessments of pharmaceutical products [50]. 
GC-MS
The short-acting insulin secretagogue commonly used as repaglinide 
for the treatment of type two diabetes. In this paper, metabolomics is 
the first research of dynamic urine metabolic profiling, and biomarkers 
of type-II antidiabetic mice treated with repaglinide based on GC-
MS. Twenty diabetic KK-Ay mice are orderly assigned to four groups 
and fed with repaglinide for 6, 9, 12, and 14 weeks, respectively. Five 
C57BL/6 J mice are used as a good healthy control group and feed with 
water as a contrast. The PCA scores plot are identified 41 metabolites 
techniques, the results are demonstrated that repaglinide not only 
regulates the carbohydrates, and polyalcohol but also the organic acid 
in the organism. This work has illustrated the potential of metabolic 
to disease diagnosis, pharmacology, and pharma codynamics research 
studies [51].
CAPILLARY ELECTROPHORESIS
An applicability method was studied by 2,6-didi-o-methyl b-cyclodextrin 
(DM-b-CD) as the Chiral selector in capillary electrophoresis for fast 
and efficient chiral separation of repaglinide enantiomers. The method 
was systematically studied of the parameters affecting separation 
was performed with detection of UV at 243 nm. The proposed new 
method was very speed and systematically, determined by efficient of 
separating enantiomers, and its applicable for the analyzing repaglinide 
enantiomers in pharmaceutical quality control of pharmaceutical 
productions [52].
The method of separation of repaglinide, brompheniramine maleate, 
dioxo promethazine hydrochloride, liarozole, carvedilol, homatropine 
hydrobromide, homatropine methyl bromide, venlafaxine, sibutramine 
hydrochloride, zopiclone, chlorphenamine maleate, and promethazine 
hydrochloride, was investigated the influence of types of ionic liquids 
concentration of BGE PH, long-chain length of ionic liquid cations on 
the resolution are explained and finally, the proposed methods were 
applied for the chiral impurity determination of Eszopiclone in the pure 
product of pharmaceutical tablets [53].
The separation of CE method in the non-aqueous medium was developed 
and validated for the determination of repaglinide in pharmaceutical 
formulation. The capillary electrophoresis was performed using a 
75 m × 90 cm fused silica capillary (76 cm effective length) and the 
detection of UV at 240 nm. 0.01 mol/l solution of ammonium acetate 
in the mixture solution of methanol-acetonitrile (3:7, v/v), 30 kV 
voltage, 30°C temperature and hydrodynamic injection (10 m bar, six s) 
was chosen as CE parameters studies. The solutions were prepared in 
methanol. The capillary electrophoresis method is demonstrated [54].
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A method of capillary electrophoresis system for enantiomeric impurity 
test of repaglinide, un-coated fused silica capillary (50 m×50 cm, with 
an effective length of (41 cm) was used. The running buffer solution 
was composed of 30 mmol/L sodium dihydrogen phosphate and 
5 mg/ml carboxymethyl-cyclodextrin (PH 3.5), and it can be used 
for determination of enantiomeric impurities in type-II antidiabetic 
[repaglinide] tablets [55].
TITRIMETRIC AND ELECTRICAL METHODS
An isocratic method was normal phase chiral HPLC method that 
was developed and validated for the enantiomeric separation of 
repaglinide, (S)- (+)-2-ethoxy-4-N [1-(2-piperidinophenyl)-3-
methyl-1-butyl] Amino carbonyl methyl] benzoic acid, an antidiabetic 
in the bulk drug substance. The solution is played an important role, 
in enhancing chromatography efficiency and resolution between 
the enantiomers. The method was developed extensively validated 
and proved to be robust. The developed method was found to 
be enantiomer selectivity, accurate, precise, and suitable for the 
quantitative determination of (R)-enantiomer in the bulk drug 
pharmaceutical substance [56].
A simple and rapid, method for a sensitive HPLC method for 
employing dual-channel colorimetric detection for the determination 
of repaglinide in human plasma is presented. The method was 
assayed by involving the extraction of repaglinide by ethyl acetate 
and its isocratic reversed-phase liquid chromatography with 
dual-channel colorimetric detection. The mobile phase solution 
composition was 50 mm disodium hydrogen phosphate/acetonitrile 
(60:40, v/v), PH of the mobile phase 7.5 set up with phosphoric acid. 
A total analysis, the first cell working potential was found to be +380 
mV, second was to be +750 mV (vs. Pd/H 2). It was confirmed that the 
method is suitable for pharmacokinetic studies or therapeutic study 
monitoring [57].
Stability-indicating studies of drugs are recognized as an essential 
part of the drug development method process. This rational study 
is used to, to understand the intrinsic stability indicating of the 
drugs and for the development of selective stability-indicating 
assay method was according to the ICH guidelines. As the stability 
stress studies of repaglinide have not been reported in the survey 
of literature review, the forced degradation product of repaglinide is 
generally carried out as per ICH guidelines, results in the formation 
of six pharmaceutical degradation products which have been 
characterized using LC-MS/MS in single and or combination with 
accurate mass measurements [58].
A method highly, sensitive and selective 3D excitation-emission of an 
accurate fluorescence technique was proposed to rapidly quantify 
the combined antidiabetics drug of repaglinide and irbesartan, and 
its application to PK study in rat and human plasmas with the Aid 
of second-order calibration curve method defending on alternating 
trilinear decomposition (ATLD) method. The enhanced excitation-
emission of matrix fluorescence light of repaglinide and irbesartan 
can be accurately solved and can simultaneously attain the optimal 
concentration level in the presence of a potentially strong intrinsic 
fluorescence from complexes biological matrices, such as human plasma 
and Rat, using the ATLD method was used, the results can be shown 
in a developed method and to maintain a second-order advantage in 
simultaneous determinations of the weak fluorescent analyses of 
interest in various biological plasma matrices study [59].
The antidiabetes mellitus and osteoarthritis both are highly 
exceptional diseases, combinations of anti-diabetic agents like 
repaglinide, and nonsteroidal anti-inflammatory drugs, like celecoxib 
which is commonly used in the treatment of clinical practice. In this 
study, a simple and sensitive bioanalytical HPLC method combined 
with a fluorescence detector (HPLC-FL) was developed and completely 
validated for the simultaneous quantification of repaglinide and 
celecoxib. A simple proteins precipitation procedure and reversed 
C18 column with an isocratic mobile phase solution (a mixture of ACN 
and PH 6.0 phosphate buffer).and stability-indicating for this method 
was determined and validated as per the current FDA guidelines. The 
bioanalytical method was applied to the study of pharmacokinetic 
interactions between repaglinide and Celecoxib in vivo study. 
Furthermore, an in vitro metabolism and protein binding study 
using human [plasma/urine]materials highlighted the possibility of 
metabolism-based interactions between Celecoxib and repaglinide in 
a study of clinical settings [60].
A rapid method of stability-indicating thin-layer chromatography 
method was developed by a quantitative analytical determination of 
repaglinide in pharmaceutical tablets dosages. Moreover, the method 
was performed on RP-8 TLC plates with acetonitrile-PH 6.0 phosphate 
buffer solution, 60 + 40% (v/v), as a mobile phase. The analytical 
method presented was found to be simple, reliable, accurate, and 
convenient for routine pharmaceutical analytical acceptance criteria 
established for TLC methods analytical performance fulfilled in the 
official literature [61].
For the point-of-care testing of the illegal fortification of repaglinide 
(Rep) in natural dietary supplements, a competitive chemiluminescent 
immunoassay (CLIA) was established, using horseradish peroxidase 
(HRP)-luminol-H2O2 system for signal amplification. Polyclonal 
antibodies for repaglinide were produced various immunizations 
technique. The method provided a result consistent with those from 
HPLC, and the proposed method could be used for rapid screening of 
repaglinide in natural dietary supplements and detecting repaglinide in 
serum after administration [62].
A method for the separation of six selected anti-hyper glycemic 
(antidiabetic) drugs (Repaglinide, tolbutamide, gliclazide, glimepiride, 
glibenclamide, and glipizide) was developed with the use of micellar 
electrokinetic chromatography. Any Two non-ionic polys (ethylene 
glycol) are based on surfactants Triton X-114 (reduced) and Genapol 
X-080 was studies are neutral pseudo stationary phases. Pseudo 
stationary phase is obtaining by negative charges of separated anti-
diabetic drugs and non-ionic surfactants were employed for selectivity 
was altered [63].
Electrochemical method of Repaglinide is described at a mercury 
electrode has been investigated using DC, DPP, and CV of Repaglinide 
Is exhibit. And well-defined as irreversible oxidation peaks over by the 
DPP was used to determine Repaglinide in pure form. The proposed 
method was exactly applied to the analysis of repaglinide in pure 
and pharmaceutical dosage forms with an average recovery of 98.8–
103.2%. The results obtained agree good with the contents stated on 
the labels [64].
The sum of unknown impurities profiles of Repaglinide bulk drug 
product are detected by a simple isocratic method is reversed-phase 
high-performance liquid chromatography method. The impurities 
are isolated from the natural crude drug of repaglinide using an RP-
HPLC method. Based on the spectroscopic data of IR, NMR, and MS 
the structures of these impurities I, II, and IV and bi-product (III) 
were characterized as 4-carboxymethyl-2-ethoxy-benzoic acid (I), 
4-cyclohexyl amino carbamoyl methyl-2-ethoxy-benzoic acid (II), 
1-cyclohexyl-3-[3-methyl-1-(2-piperidine-1-yl-phenyl)-butyl]-urea 
(IV), and 1,3-dicyclohexyl urea (III), respectively [65].
DIAGNOSIS
Diagnosis of antidiabetes can be by determining the method of 
blood glucose level. In fasting conditions, the blood glucose level 
could be >6.7 mmol/L or random glucose levels will be more than 
10 mmol/considered as diabetes. If there occur any doubts in the 
diagnosis, glucose tolerance test must be conducted to measure the 
glucose level in blood. Before the test, the patient needs to be on fast 
at least 10–12 h. During the test, the patient is advised to take 75 mg 
glucose orally the test will be repeated after 2 h. Thus, from the results 
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observed can be determined by the glucose tolerance of the patient. In 
this diagnosis and therapy process, glucose levels can be determined 
using various pharmaceutical analytical methods.
UV SPECTROSCOPY
A blood glucose level can be determined by blood with a comparison 
of the UV spectrum of normal serum and antidiabetic blood serum. 
The antidiabetes mellitus leads to be changed in the condition of 
metabolism of fats acids, carbohydrates, lipids, and proteins. Moreover, 
the blood sample solution is usually collected from normal peoples and 
diabetic people the serum is separated by centrifugation of the blood 
samples solutions. The separated serum will further be diluted with de-
ionized water and absorbance of the spectrum will be analyses [66].
LC-MS AND GC-MS
An analysis method of a 20 mL of the antecubital venous blood sample 
was collected and processed at 80°C for 6 h to take a serum sample can 
stand overnight at 4°C to achieve metabolic profiling. These samples are 
diluted to get 30 g/ml. The samples were mixed with internal standard 
and centrifuged for 10 min. The supernatant is used to metabolite 
profiling using GC-MS or LC-MS method. In the presence of amino acids 
such as a tryptophan leucine, isoleucine, and valine, free fatty acids 
such as a palmitic acid and stearic acid and glycophosphatidylinositol 
confirms the occurrence of the diabetic patient condition [67].
Recent times HbA1c, the glycated hemoglobin was considered, as an 
important marker for the diagnosis of antidiabetes. Usually, HbA1c 
analytical methods are generally used, but based on differences in 
charge or structure. The different analytical techniques are included 
ion-exchange chromatography, CE, affinity chromatography, ELISA, and 
immune assay. Other analytical techniques methods are included in 
immune turbidimetry and ion-exchange HPLC. Among these methods, 
HbA1c measured by an HPLC is significantly greater than compared to 
other immune turbidometry methods [68]. 
The assay method of a urine sample, fatty acid profiles were established 
and based on the ultra-performance liquid chromatography 
quadrupole time of flight mass spectrometer, in this way, 19 fatty 
acids are added, and two pairs of hard-resolved isomers are easily 
separated, applied in metabolomics research of diabetes mellitus. 
13 min, Q-TOF mass spectrometer reduced the matrix interference 
of urine samples by the high resolution of exact molecular weights. 
93 cases of urine samples are analyzed. This work is complementary 
to the clinical diagnosis of diabetes mellitus patients; additionally, 
non-invasive testing of urine samples made it more convenient for 
examination while decreasing the patient’s pain and improving their 
patient living conditions [69].
CONCLUSION
This review geared toward specializing in numerous analytical 
strategies according for the assay of repaglinide. A broad vary of 
techniques is out there for the estimation of repaglinide and [type-
II antidiabetics drugs] in biological samples, and pharmaceutical 
indefinite quantity type. The analysis of revealed information 
unconcealed that chemical analysis strategies are the straightforward 
and economical strategies for estimation of repaglinide in 
pharmaceutical formulation. For analysis of repaglinide, and type-
II antidiabetic medicine, HPLC-UV provides correct results and low 
price compared to advance detection techniques. HPLC with personal 
organizer detection was extensively used for the event of stability-
indicating assay strategies for separation and quantification of 
repaglinide within the presence of degradation product. This survey 
conjointly highlights the combined techniques that incorporate the 
economical separation of metabolites of repaglinide victimization 
HPLC with sensitive MS detection has become an imperative tool for 
quantification of repaglinide in biological fluids and pharmacokinetic 
studies. In comparison with activity strategies and its application of 
capillary dielectrolysis and diagnosing being thought-about as an 
alternate technique for separation of repaglinide. This review includes 
the entire detail of analytical strategies obtainable on repaglinide 
which can be substantiative for any analysis on the drug.
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